ATRA : Insider Transactions for Atara Biotherapeutics, Inc. | J3SG

Sign in:	Email	Password save:

		Company Reports
Find Symbol

Recent: Companies Filers Institutions

Membership is free, please Sign Up.

My Recent Searches

Help

Roster

Institutions

Add To Portfolo/Alerts

Get Insiders for :

Atara Biotherapeutics, Inc. (ATRA)

$0.53

0.04 (7.08%) as of 4:30 Fri 6/7

Download

Exchange:

N/A

Security Type:

N/A

Shares Out:

108,674,000

Market Cap:

57.47(M)

Last Volume:

0

Avg Vol:

0

52 Week Range:

$0.2298 - $2.31

Level I Sector:

N/A

Level II Sector:

N/A

Level III Sector:

N/A

Member Indexes:

Rankings:

Insider 3 Months : -

Insider 6 Months : -

Insider 3/6 Months : -

Guru Rank Number : 707

Guru Rank Value : 1.9

Guru Occurances : 1


6 Months 1 Year 2 Year

Company Profile Atara Biotherapeutics is engaged in T-cell immunotherapy, using its allogeneic Epstein-Barr virus (EBV) T-cell platform to develop therapies for patients with diseases, including tumors, hematologic cancers and autoimmune disease. Co.'s platform utilizes the biology of EBV T cells and has the capability to treat a range of EBV-driven diseases or other diseases through incorporation of engineered chimeric antigen receptors or T-cell receptors. Co.'s T-cell immunotherapy program, tab-cel® (tabelecleucel), is partnered with Pierre Fabre Medicament and is in Phase 3 development for patients with EBV-driven post-transplant lymphoproliferative disease.

D/I:

D is for direct shares.
I is for indirect shares.

D/I refers to the Direct or Indirect shares traded vs. held.

Forms:

A Form 4 is a form filed by an insider to indicate a change in ownership.

A Form 3 is a form filed by an insider to indicate an initial ownership of a security.

3m +/-:

This represents the company's 3 month price change. The initial price is based on the closing price of the stock on the day the transaction took place. Purchases & sales are viewed as long & short positions respectively.

Actions:

B	Buy
S	Sell
OE	Option Exercised
A	Acquired
D	Disposed
AB	Automatic Buy
AS	Automatic Sell
IO	Initial Ownership

Download:

Download only Transactions Forms. (Default)

Download only Summary Infomation.

Download both Transactions and Summary Data

Summary (Direct Transactions Only)	3 Months	6 Months	12 Months	24 Months
Total Shares Bought	0	0	816,825	816,825
Total Buy Value	$0	$0	$194,885	$194,885
Total People Bought	0	0	3	3
Total Buy Transactions	0	0	4	4
Total Shares Sold	211,204	267,396	419,842	591,605
Total Sell Value	$130,313	$170,773	$340,560	$980,941
Total People Sold	5	5	6	9
Total Sell Transactions	5	10	23	41
End Date	2024-03-10	2023-12-08	2023-06-09	2022-06-09

Adjust Filter Settings

Records found: 736

Page 20 of 30

Filer's Name

Relation Title

Off-Dir-10%

D/I

Rank

3m +/-

Form

Clark Mitchall G.

EVP & Chief R & QA Officer

• – –

2017-05-15

4

OE

$0.00

$0

D/D

7,212

156,873

-

EVP & Chief Strategy Officer

• – –

2017-05-15

4

OE

$0.00

$0

D/D

10,556

270,083

-

EVP & Chief Strategy Officer

• – –

2017-05-15

4

AS

$15.13

$105,910

D/D

(7,000)

259,527

-

Haqq Christopher

EVP, R&D & Chief Scientific Of

• – –

2017-05-15

4

AS

$14.99

$113,984

D/D

(7,604)

374,080

-

Haqq Christopher

EVP, R&D & Chief Scientific Of

• – –

2017-05-15

4

OE

$0.00

$0

D/D

829

381,684

-

Ciechanover Isaac E.

Chief Executive Officer

• • –

2017-04-26

4

AS

$17.78

$64,008

I/I

(3,600)

467,778

-

Ciechanover Isaac E.

Chief Executive Officer

• • –

2017-04-25

4

AS

$17.07

$62,397

I/I

(3,600)

471,378

-

Haqq Christopher

EVP, R&D & Chief Scientific Of

• – –

2017-04-17

4

AS

$17.28

$103,680

D/D

(6,000)

380,855

-

Ciechanover Isaac E.

Chief Executive Officer

• • –

2017-04-11

4

AS

$16.99

$71,358

I/I

(4,200)

474,978

-

Ciechanover Isaac E.

Chief Executive Officer

• • –

2017-04-10

4

AS

$17.08

$51,240

I/I

(3,000)

479,178

-

Chief Tech. Operations Officer

• – –

2017-04-03

4

A

$0.00

$0

D/D

7,500

7,500

-

Ciechanover Isaac E.

Chief Executive Officer

• • –

2017-03-28

4

AS

$18.99

$68,728

I/I

(3,600)

482,178

-

Ciechanover Isaac E.

Chief Executive Officer

• • –

2017-03-27

4

AS

$20.34

$252,216

I/I

(12,400)

485,778

-

EVP & Chief Financial Officer

• – –

2017-03-23

4

AS

$21.08

$137,020

D/D

(6,500)

112,827

-

EVP & Chief Financial Officer

• – –

2017-03-22

4

AS

$20.27

$152,025

D/D

(7,500)

119,327

-

Ciechanover Isaac E.

Chief Executive Officer

• • –

2017-03-17

4

AS

$18.50

$396,576

I/I

(20,000)

498,178

-

Ciechanover Isaac E.

Chief Executive Officer

• • –

2017-03-16

4

AS

$18.54

$200,232

I/I

(10,800)

518,178

-

Haqq Christopher

EVP, R&D & Chief Scientific Of

• – –

2017-03-15

4

AS

$19.60

$117,600

D/D

(6,000)

386,855

-

EVP & Chief Strategy Officer

• – –

2017-03-10

4

AS

$20.00

$50,000

D/D

(2,500)

266,527

-

EVP & Chief Financial Officer

• – –

2017-03-10

4

AS

$20.00

$480,000

D/D

(24,000)

126,827

-

EVP & Chief Financial Officer

• – –

2017-02-21

4

AS

$15.14

$136,260

D/D

(9,000)

150,827

-

Gallagher Carol Giltner

Director

– • –

2017-02-16

4

AS

$16.10

$19,046

D/D

(1,183)

102,192

-

EVP & Chief Strategy Officer

• – –

2017-02-16

4

AS

$15.62

$113,604

D/D

(7,273)

269,027

-

Clark Mitchall G.

EVP & Chief R & QA Officer

• – –

2017-02-16

4

AS

$15.96

$48,822

D/D

(3,059)

149,661

-

Ciechanover Isaac E.

Chief Executive Officer

• • –

2017-02-16

4

AS

$15.57

$37,368

I/I

(2,400)

348,978

-

736 Records found	Previous 20 21 22 23 24 25 26 27 28 29 Next	Page 20 of 30

	Transaction Code Key:				Ownership Code Key
	B	- Buy	AB	- Automatic Buy	D	- Direct Ownership
	S	- Sell	AS	- Automatic Sell	I	- Indirect Ownership
	OE	- Options Exercised	A	- Acquired
	IO	- Initital Ownership	D	- Disposed

Copyright © 2024 j3sg.com | Disclaimer & Terms of use Products & Service About Us Contact Us

Summary:

Chart:

3m +/-:

This represents the company's 3 month price change. The initial price is based on the closing price of the stock on the day the transaction took place. Purchases & sales are viewed as long & short positions respectively.